September 20, 2010 --
Minneapolis -- Delivering another innovation for
interventional cardiology, Medtronic, Inc. (NYSE: MDT), announced
today the U.S. Food and
Drug Administration (FDA) approval of the Integrity Coronary
Stent System.
The new platform for Medtronic’s coronary stents,
including the Integrity bare-metal stent, is based on an advance
in biomedical engineering called continuous sinusoid technology
that enables the exploration of other breakthrough device concepts
such as a polymer- free drug-filled stent. |